Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPID | Q08752 | 2/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 4/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6131684 | 0.90 | PPID (0.41) | PPIDITGB1ITGA4CTSCELANE | |
| SCHEMBL6131686 | 0.90 | PPID (0.41) | PPIDITGB1ITGA4CTSCELANE | |
| SCHEMBL6131691 | 0.87 | CTSC (0.34) | PPIDITGB1ITGA4CTSCITGB7 | |
| SCHEMBL6131689 | 0.87 | L3MBTL1 (0.36) | ITGA4ADRB2ADRB1ADRB3ITGB7 | |
| SCHEMBL4734985 | 0.80 | ITGB1 (0.43) | ITGB1ITGA4ELANEKMT2ANPSR1 | |
| SCHEMBL4750220 | 0.80 | ITGB1 (0.44) | PPIDITGB1ITGA4ELANE | |
| SCHEMBL4750224 | 0.80 | ITGB1 (0.44) | PPIDITGB1ITGA4ELANE | |
| SCHEMBL6131675 | 0.77 | MAPT (0.37) | ELANEKMT2A | |
| SCHEMBL6131693 | 0.74 | L3MBTL1 (0.36) | ITGB1ITGA4ITGB7KMT2A | |
| SCHEMBL4734039 | 0.72 | MMP1 (0.42) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951943-B2 | Process for the preparation of phenylalanine enamide derivatives | CELLTECH R & D LIMITED (GB) | 2005-10-04 | — | — | US | claimed |
| EP-1525181-A1 | PROCESS FOR THE PREPARATION OF PHENYLALANINE ENAMIDE DERIVATIVES | Celltech R & D Limited (GB) | 2005-04-27 | — | — | EP | claimed |
| US-20040073033-A1 | Process for the preparation of phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2004-04-15 | — | — | US | claimed |
| WO-2004007428-A1 | PROCESS FOR THE PREPARATION OF PHENYLALANINE ENAMIDE DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| US-6951943-B2 | Process for the preparation of phenylalanine enamide derivatives | CELLTECH R & D LIMITED (GB) | 2005-10-04 | — | — | US | disclosed |
| EP-1525181-A1 | PROCESS FOR THE PREPARATION OF PHENYLALANINE ENAMIDE DERIVATIVES | Celltech R & D Limited (GB) | 2005-04-27 | — | — | EP | disclosed |
| US-20040073033-A1 | Process for the preparation of phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2004-04-15 | — | — | US | disclosed |
| WO-2004007428-A1 | PROCESS FOR THE PREPARATION OF PHENYLALANINE ENAMIDE DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073033-A1 | Process for the preparation of phenylalanine enamide derivatives | NPY2R, NPY1R, NPR1 | PPID 3167/4885ITGB1 4148/4885ITGA4 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.